个人简历

助理研究员
所在院系：政府管理学院劳动人事与社会保障系
学术交流
· 2017.08-2018.09 美国杜兰大学 公共卫生与热带医学学院 访问学者
· 2016.07-2016.10 中国医学科学院肿瘤医院 国家癌症中心 参与城市癌症早诊早治卫生经济学评估项目
主要学术会议
· 2018年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting”，作为第一作者发表1篇会议海报.
· 2017年参加国际会议“The International Doctoral Student Conference”，作为第一作者进行口头汇报.
· 2016年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 7th Asia-Pacific Conference”，作为第一作者发表2篇会议海报.
· 2016年参加国际会议“2016 Chinese Economists Society Annual Conference”，作为第一作者进行口头汇报.
· 2016年参加国际会议“Health Technology Assessment International (HTAi) 2016 Annual Meeting”，作为第一作者进行2次口头汇报.
· 2015年参加国内会议“中华预防医学会社会医学分会第十一次全国社会医学学术年会”，作为第一作者发表1篇会议论文.
· 2015年参加国际会议“Symposium on Social Determinants of Health”，作为嘉宾在会上发言并参与讨论.
· 2015年参加国际会议“12th Health Technology Assessment International (HTAi) Annual Meeting”，作为第一作者发表1篇会议海报.
· 2014年参加国际会议“International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 6th Asia-Pacific Conference”，作为第一作者发表1篇会议海报.
· 2013年参加国内会议“中华预防医学会第四届学术年会”，作为第一作者发表1篇会议论文.

研究领域

卫生经济学、卫生技术评估、健康行为与生命质量评估、健康管理""

近期论文

· Shuyan Gu, Xiaoyong Wang, Qing Qiao, Weiguo Gao, Jian Wang, Hengjin Dong. Cost-Effectiveness of Exenatide Twice Daily vs Insulin Glargine as Add-on Therapy to Oral Antidiabetic Agents in Patients with Type 2 Diabetes in China. Diabetes Obes Metab. 2017;19(12):1688-97.
· Shuyan Gu, Yiming Mu, Suodi Zhai, Yuhang Zeng, Xuemei Zhen, Hengjin Dong. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS One. 2016;11(11):e0165629.
· Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of the Economic Burden of Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(6):533-50.
· Shuyan Gu, Yuhang Zeng, Demin Yu, Xiaoqian Hu, Hengjin Dong. Cost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in China. PLoS One. 2016;11(11):e0167190.
· Shuyan Gu, Huimei Hu, Hengjin Dong. Systematic Review of Health-Related Quality of Life in Patients with Pulmonary Arterial Hypertension. PharmacoEconomics. 2016;34(8):751-70.
· Shuyan Gu, Jing Deng, Lizheng Shi, Yiming Mu, Hengjin Dong. Cost-Effectiveness of Saxagliptin vs Glimepiride as a Second-Line Therapy Added to Metformin in Type 2 Diabetes in China. J Med Econ. 2015;18(10):808-20.
· Shuyan Gu, Jihao Shi, Zhiliu Tang, Monika Sawhney, Huimei Hu, Lizheng Shi, Vivian Fonseca, Hengjin Dong. Comparison of Glucose Lowering Effect of Metformin and Acarbose in Type 2 Diabetes Mellitus: a Meta-Analysis. PLoS One. 2015;10(5):e0126704.
· Shuyan Gu, Zhiliu Tang, Lizheng Shi, Monika Sawhney, Huimei Hu, Hengjin Dong. Cost-Minimization Analysis of Metformin and Acarbose in Treatment of Type 2 Diabetes. Value Health Reg Issues. 2015;6:84-8.

摘要收录期刊论文
· Gu S, Wang X, Shi L, Hu X, Gu Y, Huang M, Dong H. VALUING HEALTH-RELATED QUALITY OF LIFE FOR INPATIENTS WITH DIABETES-RELATED COMPLICATIONS IN CHINA. Value in Health, 2018, 21(S1): S77-8.
· Gu S, Hu H, Dong H. SYSTEMATIC REVIEW OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION. Value in Health, 2016,19(3): A118.
· Gu S, Dong H. COST-EFFECTIVENESS OF DAPAGLIFLOZIN VERSUS ACARBOSE AS A MONOTHERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898.
· Gu S, Shao H, Zeng Y, Shi L, Dong H. COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS ACARBOSE AS SECOND-LINE THERAPY IN TYPE 2 DIABETES IN CHINA. Value in Health, 2016, 19(7): A898.
· Gu S, Xu X, Shi L, Sawhney M, Hu H, Dong H. COST MINIMIZATION ANALYSIS OF CLINICAL OPTION SCENARIOS FOR METFORMIN AND ACARBOSE IN TREATMENT OF TYPE 2 DIABETES: BASED ON DIRECT AND INDIRECT TREATMENT COMPARISON RESULTS. Value in Health, 2014, 17(7): A745.
会议论文
· 顾淑燕，董恒进，杨芊，张皓，郜琳，甄雪梅，曾玉航，胡晓茜. 大气细颗粒物污染对居民造成的疾病负担的研究. 中华预防医学会社会医学分会第十一次全国社会医学学术年会, 2015.
· 顾淑燕，董恒进，杨芊，刘小方，张皓，胡慧美，王林浩，郜琳. 二甲双胍与阿卡波糖治疗2型糖尿病的文献研究. 中华预防医学会第四届学术年会, 2013.